Robyn J Hylind1, Alexandre C Pereira2,3, Daniel Quiat1,2, Stephanie F Chandler1, Thomas M Roston1, William T Pu1, Vassilios J Bezzerides1, Jonathan G Seidman2, Christine E Seidman2,4,5, Dominic J Abrams1. 1. Inherited Cardiac Arrhythmia Program, Department of Cardiology, Boston Children's Hospital (R.J.H., D.Q., S.F.C., T.M.R., W.T.P., V.J.B., D.J.A.), Harvard Medical School, Boston MA. 2. Department of Genetics (A.C.P., D.Q., J.G.S., C.E.S.), Harvard Medical School, Boston MA. 3. Laboratory of Genetics and Molecular Cardiology, Heart Institute (InCor), University of São Paulo Medical School, Brazil (A.C.P.). 4. Cardiovascular Division, Brigham and Women's Hospital (C.E.S.), Harvard Medical School, Boston MA. 5. Howard Hughes Medical Institute, Chevy Chase, MD (C.E.S.).
Abstract
BACKGROUND: Truncating variants in the desmosomal gene PKP2 (PKP2tv) cause arrhythmogenic right ventricular cardiomyopathy (ARVC) yet display varied penetrance and expressivity. METHODS: We identified individuals with PKP2tv from the UK Biobank (UKB) and determined the prevalence of an ARVC phenotype and other cardiovascular traits based on clinical and procedural data. The PKP2tv minor allelic frequency in the UKB was compared with a second cohort of probands with a clinical diagnosis of ARVC (ARVC cohort), with a figure of 1:5000 assumed for disease prevalence. In silico predictors of variant pathogenicity (combined annotation-dependent depletion and Splice AI [Illumina, Inc.]) were assessed. RESULTS: PKP2tv were identified in 193/200 643 (0.10%) UKB participants, with 47 unique PKP2tv. Features consistent with ARVC were present in 3 (1.6%), leaving 190 with PKP2tv without manifest disease (UKB cohort; minor allelic frequency 4.73×10-4). The ARVC cohort included 487 ARVC probands with 144 distinct PKP2tv, with 25 PKP2tv common to both cohorts. The odds ratio for ARVC for the 25 common PKP2tv was 0.047 (95% CI, 0.001-0.268; P=2.43×10-6), and only favored ARVC (odds ratio >1) for a single variant, p.Arg79*. In silico variant analysis did not differentiate PKP2tv between the 2 cohorts. Atrial fibrillation was over-represented in the UKB cohort in those with PKP2tv (7.9% versus 4.3%; odds ratio, 2.11; P=0.005). CONCLUSIONS: PKP2tv are prevalent in the population and associated with ARVC in only a small minority, necessitating a more detailed understanding of how PKP2tv cause ARVC in combination with associated genetic and environmental risk factors.
BACKGROUND: Truncating variants in the desmosomal gene PKP2 (PKP2tv) cause arrhythmogenic right ventricular cardiomyopathy (ARVC) yet display varied penetrance and expressivity. METHODS: We identified individuals with PKP2tv from the UK Biobank (UKB) and determined the prevalence of an ARVC phenotype and other cardiovascular traits based on clinical and procedural data. The PKP2tv minor allelic frequency in the UKB was compared with a second cohort of probands with a clinical diagnosis of ARVC (ARVC cohort), with a figure of 1:5000 assumed for disease prevalence. In silico predictors of variant pathogenicity (combined annotation-dependent depletion and Splice AI [Illumina, Inc.]) were assessed. RESULTS: PKP2tv were identified in 193/200 643 (0.10%) UKB participants, with 47 unique PKP2tv. Features consistent with ARVC were present in 3 (1.6%), leaving 190 with PKP2tv without manifest disease (UKB cohort; minor allelic frequency 4.73×10-4). The ARVC cohort included 487 ARVC probands with 144 distinct PKP2tv, with 25 PKP2tv common to both cohorts. The odds ratio for ARVC for the 25 common PKP2tv was 0.047 (95% CI, 0.001-0.268; P=2.43×10-6), and only favored ARVC (odds ratio >1) for a single variant, p.Arg79*. In silico variant analysis did not differentiate PKP2tv between the 2 cohorts. Atrial fibrillation was over-represented in the UKB cohort in those with PKP2tv (7.9% versus 4.3%; odds ratio, 2.11; P=0.005). CONCLUSIONS: PKP2tv are prevalent in the population and associated with ARVC in only a small minority, necessitating a more detailed understanding of how PKP2tv cause ARVC in combination with associated genetic and environmental risk factors.
Authors: Christopher M Haggerty; Brittney Murray; Crystal Tichnell; Daniel P Judge; Harikrishna Tandri; Marci Schwartz; Amy C Sturm; Martin E Matsumura; Michael F Murray; Hugh Calkins; Brandon K Fornwalt; Cynthia A James Journal: Circ Genom Precis Med Date: 2018-07
Authors: Francisco M Cruz; David Sanz-Rosa; Marta Roche-Molina; Jaime García-Prieto; José M García-Ruiz; Gonzalo Pizarro; Luis J Jiménez-Borreguero; Miguel Torres; Antonio Bernad; Jesús Ruíz-Cabello; Valentín Fuster; Borja Ibáñez; Juan A Bernal Journal: J Am Coll Cardiol Date: 2015-04-14 Impact factor: 24.094
Authors: Eric D Carruth; Wilson Young; Dominik Beer; Cynthia A James; Hugh Calkins; Linyuan Jing; Sushravya Raghunath; Dustin N Hartzel; Joseph B Leader; H Lester Kirchner; Diane T Smelser; David J Carey; Melissa A Kelly; Amy C Sturm; Amro Alsaid; Brandon K Fornwalt; Christopher M Haggerty Journal: Circ Genom Precis Med Date: 2019-10-22
Authors: Jasper J van der Smagt; Paul A van der Zwaag; J Peter van Tintelen; Moniek G P J Cox; Arthur A M Wilde; Irene M van Langen; Amber Ummels; F A M Hennekam; Dennis Dooijes; Frans Gerbens; Hennie Bikker; Richard N W Hauer; Pieter A Doevendans Journal: Cardiology Date: 2012-11-07 Impact factor: 1.869
Authors: Aditya Bhonsale; Judith A Groeneweg; Cynthia A James; Dennis Dooijes; Crystal Tichnell; Jan D H Jongbloed; Brittney Murray; Anneline S J M te Riele; Maarten P van den Berg; Hennie Bikker; Douwe E Atsma; Natasja M de Groot; Arjan C Houweling; Jeroen F van der Heijden; Stuart D Russell; Pieter A Doevendans; Toon A van Veen; Harikrishna Tandri; Arthur A Wilde; Daniel P Judge; J Peter van Tintelen; Hugh Calkins; Richard N Hauer Journal: Eur Heart J Date: 2015-01-23 Impact factor: 29.983
Authors: Philipp Rentzsch; Daniela Witten; Gregory M Cooper; Jay Shendure; Martin Kircher Journal: Nucleic Acids Res Date: 2019-01-08 Impact factor: 16.971